One of the most common worries about menopause hormone therapy (often called HRT) is whether it causes breast cancer. The short answer is that it depends on three things: which hormones you take, how long you take them, and your own health background. The two biggest factors are the type of progestogen (the second hormone often added to estrogen) and whether you carry a BRCA gene change. Here is what the research shows, in everyday terms.
The big picture for most women
The largest study of its kind, which combined information from more than 108,000 women with breast cancer, found that any added risk from HRT is real but usually small, and it depends a lot on the type and length of treatment.
- Estrogen by itself adds only a little risk, and that risk grows slowly the longer it is used.
- Estrogen combined with a progestogen adds more risk, and that risk shows up sooner and grows more over time.
To put it in real numbers:
- For a woman starting HRT at age 50 and taking estrogen plus a daily progestogen for five years, the chance of breast cancer over the next 20 years goes from about 6.3 percent to about 8.3 percent. That works out to roughly one extra case for every 50 women treated.
- Estrogen alone changes the numbers far less, from about 6.3 percent to about 6.8 percent, or roughly one extra case for every 200 women treated.
A major clinical trial (the Women’s Health Initiative) added an important twist that many news headlines missed. The two types of HRT actually moved in opposite directions:
- Estrogen combined with a progestin raised the risk of breast cancer.
- Estrogen alone (given to women who had already had their uterus removed) actually lowered the risk of breast cancer and lowered the chance of dying from it.
The main lesson is that HRT does not simply “cause breast cancer.” Most of the added risk comes from the progestogen, not the estrogen.
Not all progestogens are the same
This is the detail that changes the picture for many women. Progestogens come in two broad groups: micronized progesterone (sometimes called “body identical” or “bioidentical”) and synthetic progestins (such as medroxyprogesterone acetate, norethindrone, or levonorgestrel).
- A large UK study found that estrogen plus micronized progesterone was not linked to a higher breast cancer risk, while estrogen plus a synthetic progestin was.
- A large French study found no increased risk with estrogen plus micronized progesterone when used for six years or less, but a clear increase with synthetic progestins.
- A recent review concluded that micronized progesterone and a related option called dydrogesterone were consistently linked to lower breast cancer risk than synthetic progestins.
Two cautions keep this from being fully settled:
- The advantage seems to fade with time. In the French study, the reassuring signal for micronized progesterone disappeared after about six years of use.
- Most of this evidence comes from observational studies, not the strongest type of trial. Some data even found micronized progesterone looked similar to synthetic progestins in the medium term, and no top-tier trial has proven it is safer.
A fair summary: estrogen plus micronized progesterone probably carries less risk than synthetic combinations and appears reasonably safe for about five years, but this is not proven by the strongest studies and likely offers no protection with long-term use.
Women who carry a BRCA gene change
Women with a BRCA1 or BRCA2 gene change often have their ovaries and tubes removed in their late 30s or 40s to lower cancer risk. This puts them into early menopause. A natural worry is that adding hormones back could raise their already higher breast cancer risk. The research is largely reassuring, at least for shorter-term use.
- One study comparing BRCA carriers found fewer breast cancers among HRT users than non-users. Estrogen alone was linked to a clearly lower risk, and estrogen plus a progestogen did not raise risk.
- Another recent study of more than 900 carriers found that having used HRT did not raise breast cancer risk, and that each year of estrogen-only therapy actually lowered risk, especially in BRCA1 carriers.
There is a biological reason for this. BRCA1-related cancers are often the “triple-negative” type and appear to be driven partly by progestin signaling, which may explain why estrogen alone looks neutral or even protective. In BRCA2 carriers, whose tumors are more often hormone-sensitive, the picture is less clear, partly because these groups have been smaller in studies.
One safety point stands out: carriers who had their ovaries removed before age 45 and then used estrogen plus a progestin for five or more years showed a possible increase in risk. This reinforces two themes across all the research: length of use matters, and estrogen alone is the safer choice once the uterus has been removed.
What professional guidelines recommend
- The National Comprehensive Cancer Network says HRT is generally not off-limits for BRCA carriers who have not had breast cancer, and that it should be openly discussed. When the uterus has been removed, estrogen alone is preferred. When the uterus is still present, options include a hormone-releasing IUD (levonorgestrel, a progestin), a combined estrogen and progesterone approach with attention to the uterine lining, or estrogen combined with a medicine called bazedoxifene.
- The American College of Obstetricians and Gynecologists and gynecologic oncology and fertility groups similarly recommend offering hormone therapy to carriers who have not had breast cancer, to ease the effects of early surgical menopause. They note that a few years of therapy does not meaningfully cancel out the cancer-prevention benefit of removing the ovaries, while acknowledging that long-term safety data are limited.
Practical bottom line
- The formulation is the main lever. Estrogen alone is neutral to protective in both the general population and BRCA carriers. Combined regimens carry more risk, but estrogen plus micronized progesterone appears more favorable than synthetic-progestin combinations, at least for about five years.
- Carrying a BRCA gene change is not an automatic reason to avoid HRT. For carriers who have not had breast cancer, shorter-term HRT after ovary removal does not appear to raise breast cancer risk and may even lower it, especially with estrogen alone in BRCA1 carriers.
- Duration and personal history are the key guardrails. The most reassuring data cover use up to about five years, or up to the natural age of menopause. HRT is generally avoided in women who have had breast cancer, especially the hormone-sensitive type.
These are averages across large groups of people. The right choice is a personal one, made with your clinician, weighing your menopause symptoms, bone, brain and heart health, whether you still have a uterus, your specific BRCA type, and what matters most to you.
